Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02087826 · ClinicalTrials.gov registry record · NA
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
A NA study of Type 2 Diabetes and Metabolism, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 1,017
- Enrollment target
- 1
- Study location
NCT02087826: Active NA study of Type 2 Diabetes and Metabolism, sponsored by Massachusetts General Hospital.
NCT02087826 is a NA study of Type 2 Diabetes and Metabolism that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,017 participants, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02087826, a NA study of Type 2 Diabetes and Metabolism, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,017 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to examine whether specific genes (e.g. SLC16A11) affect how human beings respond to food and a medication that is commonly used to treat type 2 diabetes. The food the investigators will be studying is specially prepared to contain protein, carbohydrate, and fat. The drug the investigators are studying is metformin. The investigators hypothesize that physiological responses to the meal and to the medication will differ between carriers and non-carriers of genes associated with type 2 diabetes.
Primary Outcome
Primary endpoint point: 2 hr glucose after the MMTT Secondary endpoints: 2 hr insulin after the MMTT, change in glucose, insulin, and amino acid and lipid metabolites from baseline to 60 and 120 minutes after the MMTT; change in GLP-1 concentrations from baseline to 5,10, 15, 30, 60, and 120 minutes after the MMTT; and glucose, insulin, and GLP-1 AUC over 120 minutes
Conditions Studied
Interventions
- DRUG Metformin
- OTHER Mixed Meal Tolerance Test
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,017 participants |
| Start Date | 2014-04 |
| Est. Completion | 2026-12 |
| Phase | NA |
What the registry record for NCT02087826 still lists
NCT02087826 is an interventional study that assigns participants to a tested intervention. Its 1,017 participants enrollment target places it among the larger protocols in the corpus, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Metformin is the first listed.
NCT02087826 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02087826 about?
NCT02087826 is a clinical study titled "Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS". The purpose of this research study is to examine whether specific genes (e.g. SLC16A11) affect how human beings respond to food and a medication that is commonly used to treat type 2 diabetes. The food the investigators will be studying is specially prepared to contain protein, carbohydrate, and fat...
What is the current status of trial NCT02087826?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,017 participants. The study started on 2014-04. Estimated completion is 2026-12.
What conditions does trial NCT02087826 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Metabolism, Genetics.
What interventions are being tested in trial NCT02087826?
The interventions under investigation include: Metformin (DRUG), Mixed Meal Tolerance Test (OTHER).
Who is sponsoring clinical trial NCT02087826?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02087826 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02087826's enrollment target sits among peer trials
1,017 23rd of 327 higher than 305 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia